Pharma split: The Tipline for 18 November 2019
We had a split decision at the Federal Trade Commission. The agency voted 3-2 to order drugmakers Bristol-Myers Squibb and Celgene divest psoriasis drug Otezla as a condition for the companies’ proposed $13.4 billion merger. Commissioners Rohit Chopra and Rebecca Slaughter offered dissenting opinions, arguing a “status quo” merger analysis is not enough to address all the potential harms of the deal.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10